TUSTIN, CA--(Marketwired - Jun 17, 2015) - Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc., today announced its participation at the Biotechnology Industry Organization's (BIO) International Convention being held at the Philadelphia Convention Center, in Philadelphia, Pennsylvania, June 15 - 18, 2015. At this global biotechnology event, Avid will present in the BioProcess theater forum its strategy in designing and building a state-of-the-art commercial manufacturing facility that was designed to utilize 100% single-use, disposable technologies.
Avid's new facility is designed for late phase III and commercial production for biological products expressed from mammalian cell lines. The facility incorporates monolithic modular clean room walls, dedicated support utilities for each key processing step, and the latest in single-use technology, which can accommodate multiple single-use bioreactors, up to 2,000 liter scale. The facility is located adjacent to the company's current campus in Orange County, California and is expected to begin production by mid-2015.
"The annual gathering at BIO allows us to share the newest additions to Avid's services portfolio and highlight the upcoming launch of our new state of the art single-use facility. The new production facility was designed to be one of the first US late phase III clinical and commercial production facilities for the exclusive operation of single-use equipment to produce biologics," said Steve King, President and CEO at Avid Bioservices. "The new facility uses the most advanced modular cleanroom and single-use production systems and was designed to meet both US and international regulatory requirements. We have already seen tremendous interest for production in the new facility, both from new and existing clients and we look forward to launching production in the near future."
The presentation in the BioProcess Theater program will enable attendees to hear about the strategy and considerations that went into designing this new facility for late phase III and commercial production and the flexibility offered by the modular cleanroom bioproduction suites that allowed the company to construct this new facility in a shorter timeframe than the typical facility build-out and commissioning.
Details on Avid's presentation at the BioProcess Theater within the BioProcess Zone:
Title: "Designing & Implementing a New State-of-the-Art Single-Use Facility for Late Phase III & Commercial Production"
Speaker: John Haney, Senior Project Manager, Avid Bioservices, Inc.
Date: Wednesday, June 17, 2015
Time: 3:30 PM - 3:55 PM Eastern Time
In addition, as part of the biopartnering forum, Avid Bioservices (Booth # 533) will be conducting one-on-one partnering meetings with industry colleagues. If you are a company wishing to meet with Avid during BIO, please submit a partnering request through the BIO partnering system.
For additional information on the BIO International Convention, please visit: http://convention.bio.org/
About Avid Bioservices
Avid Bioservices provides a comprehensive range of high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 15 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, final product filling, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. For more information about Avid, please visit www.avidbio.com.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. For more information, please visit www.peregrineinc.com.